menu
    • menu
    [{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Ellipses Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"SRB22","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Ellipses Pharma Limited","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Ellipses Pharma Limited"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"SRB19","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ SunRock Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ SunRock Biopharma"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"SRB21","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Debiopharm"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"SRB21","moa":"HER2\/HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Debiopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by SunRock Biopharma

    Menu

    SunRock Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRB21

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody

                            Details : Debiopharm has exercised its option to license SRB21, SunRock Biopharma's bispecific antibody, which targets both HER2 and HER3 human epidermal growth factor receptors.

                            Product Name : SRB21

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 30, 2025

                            Lead Product(s) : SRB21

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRB19

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Debiopharm Extends Partnership with SunRock for HER3 Targeted Antibody

                            Details : SunRock will develop SRB19, a HER3-EGFR bispecific antibody-drug conjugate for head and neck cancer, using Debiopharm's Multilink technology.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : SRB19

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRB21

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers

                            Details : Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody dr...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 21, 2023

                            Lead Product(s) : SRB21

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            SunRock Biopharma

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRB22

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ellipses Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:...

                            Details : Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 25, 2022

                            Lead Product(s) : SRB22

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ellipses Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth